CBIV and EIFO led a €30m Series B round in Bactolife.

CBIV, an impact venture capital firm, and EIFO, a financial services provider, led a €30m Series B round in Bactolife, a Danish biotech company, with participation from Novo Holdings and Athos. “Today’s successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026. This funding will enable us to clinically validate, scale, and commercialize our Binding Proteins, taking Bactolife’s solutions to a broad audience. We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission. We are ready to transform gut health with novel Binding Proteins,” Sebastian Søderberg, Bactolife CEO.